A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome

Table 5 CR rates of CAG and non-CAG regimens in AML patients

Study	Year	Total No. patients	No. Patients		No. CR		CR %
			CAG	Non-CAG	CAG	Non-CAG	CAG	Non-CAG
Saito [35]	1995	35	18	17¹	15	11	83	65
Chen [46]	2008	75	34	41²	23	16	68	39
Sang [47]	2008	45	23	22³	9	7	39	32
Bian [48]	2008	46	26	26⁴	20	10	77	38
Zhu [50]	2009	50	30	20⁵	14	6	47	30
Li [53]	2010	38	18	20⁶	14	14	78	70
Feng [52]	2010	32	16	16⁷	9	7	56	44

Abbreviation: AML: acute myeloid leukemia; CR: complete remission; CAG: cytarabine, aclarubicin and G-CSF;
1: HD-Ara-C+M/ME (high-dose cytarabine plus mitoxantrone with or without etoposide);
2: TA/HA (pirarubicin plus cytarabine/homoharringtonine plus cytarabine);
3: DA/HA/IA (daunorubicin plus cytarabine/homoharringtonine plus cytarabine/idarubicin plus cytarabine);
4: DAH/MAE (daunorubicin plus cytarabine plus homoharringtonine/mitoxantrone plus cytarabine plus etoposide);
5: DA/IA/MA (daunorubicin plus cytarabine/idarubicin plus cytarabine/mitoxantrone plus cytarabine);
6: HAG (homoharringtonine plus cytarabine plus GCSF);
7: HA (homoharringtonine plus cytarabine).

ISSN: 1756-8722